The company that looked at the peptide - the molecule textbooks called too fragile to be a drug - and decided to make it the hero of the story.
In a low-slung building off Gateway Boulevard in Newark, California, roughly 130 people spend their days arguing with chemistry. The argument is old and the conventional wisdom is stubborn: peptides - those short chains of amino acids the body makes by the millions - are too delicate to be medicines. They get chewed up in the gut. They vanish from the bloodstream. They were, for decades, the molecule everyone admired and nobody could ship.
Protagonist Therapeutics built a company on disagreeing. Its premise is almost literary - take the supporting character of drug discovery and hand it the lead role. Hence the name. The peptide is the protagonist, and the plot is unmet medical need.
Developing life-changing peptide drug therapies.- Protagonist Therapeutics, company tagline
That is a tidy sentence for a deeply untidy science. To make a peptide behave like a drug, you have to engineer it to survive - to resist the enzymes that would shred it, to stay potent, to hit one target and ignore the rest, and ideally, to do all of that after being swallowed rather than injected. Protagonist's proprietary discovery and engineering platform, with roots in the Vectrix scaffold technology brought in by co-founder Mark Smythe, exists to win exactly those fights.
A platform is only as interesting as what comes off it. Protagonist's portfolio reads like three different bets placed by the same hand - blood, inflammation, and metabolism - all played with peptides.
An injectable hepcidin mimetic for polycythemia vera - a blood disorder where the body makes too many red cells. The NDA is accepted under FDA Priority Review with a target action date in Q3 2026, aiming to retire the phlebotomy chair.
A first-in-class oral peptide that blocks the IL-23 receptor for psoriasis, psoriatic arthritis and ulcerative colitis. Developed with Janssen / Johnson & Johnson; reached the U.S. market in March 2026. An IL-23 blocker you swallow, not inject.
An oral and subcutaneous triple GLP-1 / GIP / GCG receptor agonist for obesity and weight management - peptides aimed squarely at the busiest corner of modern pharma.
The proprietary discovery and engineering system that makes the rest possible: potent, selective, metabolically stable, and frequently oral peptide candidates designed from the molecule up.
Drug developers have long faced a choice between two imperfect tools. Small molecules are cheap and oral but blunt. Biologics (antibodies) are precise but big, injected, and expensive. Peptides sit in the middle - and Protagonist's bet is that the middle, engineered well, is the best seat in the house.
We improve patients' lives through the power of peptide drug discovery and development.- Protagonist Therapeutics, mission
Built on proprietary peptide technology, with scientific roots tracing to academic work in Australia and the University of Pennsylvania.
Joins as President & CEO, providing the long-running strategic leadership that still steers the company.
Moves from private biotech to public company, fueling clinical development across the pipeline.
Named among the most innovative biotechnology companies in the world.
Icotrokinra reaches the U.S. market for plaque psoriasis; rusfertide sits under Priority Review with a Q3 PDUFA date. J&J is reported in active acquisition discussions.
Protagonist runs a hybrid model: discover its own drugs, and partner the ones that need a giant's reach. The headline alliance is with Janssen / Johnson & Johnson on icotrokinra - a deal worth up to $855 million in development and commercialization milestones, plus tiered royalties of roughly 6-10% on worldwide sales. ICOTYDE's approval alone triggered a $50 million milestone payment, with up to $580 million in milestones still ahead.
It is the kind of arrangement that lets a 130-person company in Newark stand behind a globally launched drug - and the reason a company the size of J&J is reportedly circling for an outright acquisition.
Co-developer of icotrokinra. Up to $855M in milestones plus tiered royalties; reported in active acquisition talks as of March 2026.
Largely collaboration milestones and royalties - the economics of a company whose products are just now reaching the market.
Newark, California; Cambridge, Massachusetts; and Osaka, Japan.
Interviews, science explainers and disease-area context. (Links open YouTube searches for the most current videos.)
Walk back to that low building in Newark. The argument with chemistry is still going - it always will be, that's the job. But the terms have changed. A peptide the textbooks said could never survive a stomach is now a pill on pharmacy shelves. A blood disorder treated for years with a needle and a bag is waiting on a single FDA decision. And the molecule everyone admired but nobody could ship has, in at least one case, shipped.
The supporting character got the lead role after all. Which, for a company called Protagonist, is the only ending that was ever going to do.